149 related articles for article (PubMed ID: 38198130)
1. Causes and Clinical Presentation of Drug-Induced Dermatomyositis: A Systematic Review.
Caravan S; Lopez CM; Yeh JE
JAMA Dermatol; 2024 Feb; 160(2):210-217. PubMed ID: 38198130
[TBL] [Abstract][Full Text] [Related]
2. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
3. Management of Cutaneous Immune-Related Adverse Events in Patients With Cancer Treated With Immune Checkpoint Inhibitors: A Systematic Review.
Nadelmann ER; Yeh JE; Chen ST
JAMA Oncol; 2022 Jan; 8(1):130-138. PubMed ID: 34709352
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Dermatomyositis induced by drug therapy: a review of case reports.
Seidler AM; Gottlieb AB
J Am Acad Dermatol; 2008 Nov; 59(5):872-80. PubMed ID: 18625537
[TBL] [Abstract][Full Text] [Related]
6. Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review.
Yu K; Wang T; An D; Li X; Tang Z
Semin Arthritis Rheum; 2024 Aug; 67():152478. PubMed ID: 38833729
[TBL] [Abstract][Full Text] [Related]
7. Hydroxyurea induced dermatomyositis-like eruption.
Zappala TM; Rodins K; Muir J
Australas J Dermatol; 2012 Aug; 53(3):e58-60. PubMed ID: 22881475
[TBL] [Abstract][Full Text] [Related]
8. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
Gerami P; Schope JM; McDonald L; Walling HW; Sontheimer RD
J Am Acad Dermatol; 2006 Apr; 54(4):597-613. PubMed ID: 16546580
[TBL] [Abstract][Full Text] [Related]
9. Statin-induced dermatomyositis for the practicing dermatologist: a review of the literature.
Visconti MJ; Bashyam AM; Jorizzo JL
Int J Dermatol; 2020 Mar; 59(3):383-387. PubMed ID: 31840246
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
He C; Li W; Xie Q; Yin G
Front Immunol; 2021; 12():820163. PubMed ID: 35116041
[TBL] [Abstract][Full Text] [Related]
11. Dermatomyositis and colorectal cancer: a systematic review.
Gkegkes ID; Minis EE; Iavazzo C
Ir J Med Sci; 2018 Aug; 187(3):615-620. PubMed ID: 29168152
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk in dermatomyositis: a meta-analysis of cohort studies.
Olazagasti JM; Baez PJ; Wetter DA; Ernste FC
Am J Clin Dermatol; 2015 Apr; 16(2):89-98. PubMed ID: 25721032
[TBL] [Abstract][Full Text] [Related]
13. [Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea].
Martorell-Calatayud A; Requena C; Nagore-Enguídanos E; Guillén-Barona C
Actas Dermosifiliogr; 2009 Nov; 100(9):804-7. PubMed ID: 19889302
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea-induced dermatomyositis-like eruption.
Senet P; Aractingi S; Porneuf M; Perrin P; Duterque M
Br J Dermatol; 1995 Sep; 133(3):455-9. PubMed ID: 8547004
[TBL] [Abstract][Full Text] [Related]
15. Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
Inoue M; Tanboon J; Hirakawa S; Komaki H; Fukushima T; Awano H; Tajima T; Yamazaki K; Hayashi R; Mori T; Shibuya K; Yamanoi T; Yoshimura H; Ogawa T; Katayama A; Sugai F; Nakayama Y; Yamaguchi S; Hayashi S; Noguchi S; Tachimori H; Okiyama N; Fujimoto M; Nishino I
JAMA Neurol; 2020 Jul; 77(7):872-877. PubMed ID: 32310254
[TBL] [Abstract][Full Text] [Related]
16. Dermatomyositis presenting with severe subcutaneous edema: five additional cases and review of the literature.
Milisenda JC; Doti PI; Prieto-González S; Grau JM
Semin Arthritis Rheum; 2014 Oct; 44(2):228-33. PubMed ID: 24830790
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
Kim Y; Park D; Choi SY; Chung C
Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
[TBL] [Abstract][Full Text] [Related]
18. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
19. Dermatomyositis-like eruption induced by hydroxyurea: a case report.
Janerowicz D; Czarnecka-Operacz M; Stawny M; Silny W
Acta Dermatovenerol Alp Pannonica Adriat; 2009 Sep; 18(3):131-4. PubMed ID: 19784527
[TBL] [Abstract][Full Text] [Related]
20. The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature.
Fejza A; Carobolante G; Poletto E; Camicia L; Schinello G; Di Siena E; Ricci G; Mongiat M; Andreuzzi E
Front Immunol; 2023; 14():1270981. PubMed ID: 37854588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
